Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28571116 | 1.00 | KDM4E (0.44) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14154741 | 1.00 | KDM4E (0.44) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7173060 | 0.96 | KDM4E (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7171375 | 0.96 | KDM4E (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7181522 | 0.96 | KDM4E (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7179383 | 0.96 | KDM4E (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7176802 | 0.96 | KDM4E (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7173073 | 0.96 | KDM4E (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7173290 | 0.96 | KDM4E (0.42) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5945715 | 0.86 | ALDH1A1 (0.50) | KDM4EMAPTNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787971-A2 | Process for preparing aryl allyl ethers | Dow Gloval Technologies Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1546078-A1 | PROCESS FOR PREPARING ARYL ALLYL ETHERS | Dow Global Technologies Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050033094-A1 | Process for preparing aryl allyl ethers | BORIACK CLINTON J (US) | 2005-02-10 | — | — | US | disclosed |
| EP-1080084-B1 | PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS | DOW GLOBAL TECHNOLOGIES INC (US) | 2004-05-06 | — | — | EP | disclosed |
| WO-2004013076-A1 | PROCESS FOR PREPARING ARYL ALLYL ETHERS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024263-A1 | Process for preparing aryl allyl ethers | BORIACK CLINTON J (US) | 2004-02-05 | — | — | US | disclosed |
| CN-1303382-A | Epoxidation process for aryl allyl ethers | DOW CHEMICAL CO (US) | 2001-07-11 | — | — | CN | disclosed |
| EP-1080084-A2 | PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS | THE DOW CHEMICAL COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6087513-A | REACTION OF ALLYL ARYL ETHER WITH HYDROGEN PEROXIDE IN THE PRESENCE OF TRANSITION METALS FOR OXIDATION | THE DOW CHEMICAL COMPANY (US) | 2000-07-11 | — | — | US | disclosed |
| WO-1999062894-A2 | PROCESS FOR EPOXIDATION OF ARYL ALLYL ETHERS | THE DOW CHEMICAL COMPANY (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024263-A1 | Process for preparing aryl allyl ethers | PICALM, AP2M1, AP1M1 | KDM4E 630/4885MAPT 1368/4885NPC1 2043/4885 |
| US-20050033094-A1 | Process for preparing aryl allyl ethers | PICALM, AP2M1, AP1M1 | KDM4E 630/4885MAPT 1368/4885NPC1 2043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.